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R egulatory maintenance of metabolic homeostasis is critically regulated at the transcriptional level (). In response to the daily energetic demands, interdependent transcriptional regulators and coregulators transduce upstream nutritional cues to dozens of metabolic gene programs responsible for dynamically balancing energy intake, circulation, storage, and expenditure. Together, these factors subserve cellular function in disparate organs in a cooperative and specific fashion to ultimately () generate whole-body responses, () restrain extreme metabolic fluctuations, and () deliver energetic substrates appropriately in response to changes in physiologic state, such as fasting or exercise. This impressive transcriptional regulatory activity, requisite for mammalian life, can achieve high levels of specificity via multiple mechanisms, including context-dependent recruitment of coactivators or repressors, tissue-restricted expression, and factor-specific cistromes; recent evidence also points to the role of posttranslational modifications in tuning transcription factor activity ().
Studies over the past several decades have underscored the importance of particular transcriptional gene families in metabolic regulation (-). For example, nuclear factors such as the peroxisome proliferatoractivated receptors (PPARs), estrogen-related receptors (ERRs), nuclear respiratory factors, CCAAT/element binding proteins (C/EBPs), and the sterol regulatory element binding protein (SREBP) are essential players in metabolic regulation by binding to specific DNA sequence motifs and associating with coregulators in a context-dependent fashion (-).
Beyond the canonical ligand-gated nuclear receptors, a new family of metabolic regulators has emerged in recent years: the Krüppel-like factors (KLFs). The KLFs are a family of phylogenetically conserved, broadly expressed transcription factors involved in diverse physiological and pathological processes. This transcription factor family initially was identified by the single Drosophila melanogaster protein Krüppel, and the current  members each contain three zinc finger motifs of the C  H  type, which recognize GCrich DNA binding sequences and transactivate or repress gene expression. Thousands of KLF response elements are scattered throughout the genome, prohibiting specificity arising from DNA binding motifs. Thus, like the aforementioned ligand-gated nuclear factors, the KLFs use coactivators and corepressors to apply additional regulation to KLF-mediated transcriptional output. These mechanisms, such as posttranslational regulation and descriptions of KLF-associated protein partners, and their roles in wide-ranging KLF biology, are well reviewed elsewhere (, ).
Molecular investigations of adipocyte maturation were the first to reveal a link between the KLFs and metabolism (). Subsequent work has expanded the purview of KLF regulation into nearly every aspect of systemic metabolism. The KLFs are expressed in multiple metabolically active organs, are exquisitely responsive to nutrient status, and exert broad and robust transcriptional control over glucose, lipid, and amino acid nutrient handling. In addition, recent evidence also suggests the KLFs are highly cooperative with other families of metabolic regulators (i.e., the nuclear receptors).
Here, we summarize current understanding of KLFs in the regulation of energy metabolism through control of nutrient intake and acquisition, systemic circulation, and tissue-specific utilization, and discuss how KLFs orchestrate complex physiologic responses such as fasting. First, KLFs located both centrally and peripherally modulate energy intake through feeding behavior. Upon entry into the postprandial state, gut and liver KLFs control a range of functions from bile synthesis to intestinal stem cell maintenance to effect intestinal absorption. Subsequently, KLF activity across multiple organs responds to changes in nutrient status to coordinate distribution of nutrients to sites of storage or liberation for use. Finally, in energy-consuming organs like cardiac and skeletal muscle, KLFs tune local metabolic programs to precisely match energetic demand with substrate uptake, flux, and use; this is achieved in part through circulating mediators, including glucocorticoids and insulin, and through modulation of mitochondrial function. Together, the KLFs orchestrate systemic metabolism through local and multiorgan transcriptional regulation of each macronutrient class.
Energy Intake
Appetite control The drive to consume is seated in the brain. Eating behavior is sensitive to homeostatic feedback from hormones released peripherally in response to nutrient status; this feedback is an essential mechanism to control food intake and maintain metabolic homeostasis. Two hormones reciprocally signal through the hypothalamus to modulate food intake behavior and are subject to KLF transcriptional control: ghrelin and leptin ( Fig. a) . Originating primarily from specialized cells within the gastrointestinal (GI) tract, ghrelin secretion rises with fasting and falls upon feeding (). Ghrelin stimulates orexigenic neuropeptide Y and Agouti-related protein (AgRP) neurons to augment appetite (). Conversely, the adipokine leptin inhibits neuropeptide Y and AgRP neurons while stimulating anorexigenic pro-opiomelanocortin neurons within the arcuate nucleus of the hypothalamus ().
KLF expression within the GI tract increases in response to fasting and correlates with ghrelin levels (). Mechanistically, KLF associates with the fastinginducible cAMP response element binding protein (CREB) to directly regulate mRNA transcript levels of ghrelin, and silencing KLF greatly reduces ghrelin expression in stimulated human gastric cells (). Centrally, KLF also propagates orexigenic signals while limiting anorexigenic signals like leptin. Within AgRP neurons, KLF expression increases during fasting to elevate appetite and promote food intake via direct regulation of AgRP expression in arcuate nucleus neurons independent of Forkhead Box O (FoxO) (). Leptin suppresses endogenous KLF expression through a STAT-mediated pathway; conversely, forced expression of KLF in the arcuate ESSENTIAL POINTS · Metabolic homeostasis is tightly regulated at the transcriptional level by a complex network of transcription factors and coregulators · The Krüppel-like factors (KLFs) affect the metabolism of nearly every macronutrient, including carbohydrates, lipids, and amino acids · KLFs are a new family of metabolic regulators that interact with classically studied regulators of metabolism, including nuclear receptors to facilitate metabolic transcription · KLFs orchestrate systemic metabolic homeostasis through transcriptional control of key processes in metabolism, including nutrient uptake, interorgan trafficking, and tissue utilization · Many KLFs are responsive to states of nutrient excess or debt, which allows them to serve as metabolic switches, shifting metabolism between nutrient storage and liberation · Variants of numerous KLFs are implicated in human metabolic disease, making them important targets of investigation nucleus of rats reduces sensitivity to exogenous leptin (). Thus, KLF seems to favor increased food intake behavior through its activities both in the GI tract and in the hypothalamus. Although many models of dietinduced obesity demonstrate that satiety signals within the hypothalamus are negatively affected by high-fat diet, hypothalamic KLF levels do not respond to a high-fat diet regimen-evidence that food intake is a complex behavior subject to layers of control.
In addition to ghrelin and leptin signaling, there is growing appreciation for other local and circulating mediators of appetite that are under KLF control. KLF has a repressive role in the expression of several adipokines, including leptin (). KLF inhibits expression of adiponectin and insulin, both of which suppress appetite centrally (-). Multiple KLFs control insulin production and sensitivity. The specific mechanisms behind this are discussed in a later section in this article; however, this regulation is noteworthy in the setting of appetite regulation because the effects of KLF-regulated insulin dynamics likely extend to the hypothalamus, expanding the influence that KLFs have on feeding behavior.
Intestinal absorption
In response to nutrient entry into the duodenum, liver-derived bile acids are secreted into the intestine to facilitate absorption of lipids and fat-soluble vitamins while also serving as a route for excess cholesterol to leave the body. In diseases that affect the liver or biliary tree, such as biliary cholangitis and cirrhosis, suboptimal levels of concentrated bile are released into the small intestine, resulting in impaired lipid absorption and consequent lipid deficiency. Bile acid synthesis, therefore, represents a critical point for transcriptional regulation in metabolic homeostasis. Bile acids act as ligands for nuclear receptors residing in the intestine, such as the farnesoid X receptor (FXR). Activated ileal FXR promotes the expression and secretion of the enterokine fibroblast growth factor  (Fgf) () into the circulation, which travels to the liver to repress Cypa, the rate-limiting enzyme in bile acid production (). KLF constitutes a regulatory pathway that controls bile acid pools and lipid and vitamin absorption independent of FXR ( Fig. b) . Ileal KLF suppresses expression of Fgf to promote bile acid synthesis via Cypa; Klf 2/2 mice exhibit reduced tissue bile acid levels simultaneous with deficiencies in triglyceride and cholesterol absorption, which are corrected upon ileectomy (). In addition, KLF expression varies diurnally and, therefore, drives the long-observed rhythmicity of Fgf and Cypa gene expression (, ). To date, intestinal KLF is, to our knowledge, the only negative transcriptional regulator of bile acid production.
Epithelial barrier function and regenerative potential allow the intestine to be selectively permeable to nutrients while excluding luminal microbes. Intestinal transporters are also essential to ensuring selective uptake of nutrients ( Fig. c) . KLF regulates the expression of multiple nutrient transporters, including those for zinc, folate, and biotin absorption (-). KLFs are critical in the maintenance of proper intestinal barrier function. For example, KLF and KLF demonstrate reciprocal effects on intestinal stem cell Figure 1 . KLF regulation of nutrient acquisition and absorption. (a) Multiple KLFs regulate appetite and feeding behavior centrally and peripherally. Within the hypothalamus, KLF4 expression promotes expression of AgRP to stimulate appetite. Anorexigenic hormones such as leptin inhibit neuronal KLF4 expression, thereby reducing appetite. Peripherally, KLF4 is induced by fasting and cooperates with CREB to augment ghrelin production. This, in turn, propagates orexigenic signaling in the brain. In addition, KLF7 inhibits production of key satiety-mediating factors that would otherwise ultimately signal through POMC neurons to reduce feeding. (b) Intestinal KLF15 promotes hepatic bile acid production through a feedback loop involving inhibition of FGF15 production within the intestines, ultimately relieving FGF15-mediated inhibition of CYP7A1. This reduces intestinal absorption of triglycerides and cholesterol. (c) Intestinal KLFs regulate proper barrier function and absorptive capacity. KLF4 increases specific nutrient transporters to maintain a pool of important cofactors for many metabolic processes. These include zinc, biotin, and folate transporters. Intestinal barrier function is preserved through a coordination of intestinal stem cell selfrenewal and eventual differentiation. KLF5 expression in the crypts maintains available populations of intestinal stem cells. Conversely, KLF4 expression is highest at the villi tips and is associated with intestinal cell differentiation. Abbreviations: AgRP, Agouti-related peptide; BA, bile acid; CREB, cAMP response element binding protein; CYP7A1, cytochrome P450 family 7 subfamily A member 1; FGF15, fibroblast growth factor 15; NPY, neuropeptide Y; POMC, pro-opiomelanocortin; TG, triglyceride; chol, cholesterol. [© 2019 Illustration Presentation ENDOCRINE SOCIETY] proliferation and differentiation. Originally termed "gut KLF," KLF expression occurs in a gradient across the intestinal villus, correlating strongly with increasing degree of differentiation, with highest expression in the tips of the villi (-). In contrast, KLF is enriched in proliferating crypt cells, and loss of intestinal KLF expression impairs the intestinal stem cell niche (-). Therefore, balanced activity of these two factors throughout the epithelial stem cell life cycle maintains intestinal homeostasis. In addition, KLF directly regulates intestinal barrier function. Loss of intestinal KLF is associated with barrier breakdown and increased permeability, in part through regulation of desmoglein-, a desmosomal component (, ).
Through the mechanisms described in this section, the KLFs govern eating behavior and subsequent intestinal absorption of nutrients, which, together, affect organismal energy intake. This KLF regulation of energy intake also responds to circulating signals of nutrient status (e.g., to mediate satiety in nutrient replete states). Entry of nutrients into the circulation engages hormonal regulatory mechanisms linked to a new suite of KLF-mediated transcriptional programs in various metabolic organs to handle and distribute energy.
Systemic Nutrient Trafficking
Circulating mediators Nutrient trafficking in states of energy debt or surplus is mediated by hormonal signals. Insulin is a powerful anabolic hormone; insulin levels rise in the fed state and stimulate glucose uptake into tissues, glycogen synthesis in the liver and skeletal muscle (lowering blood glucose levels), and triglyceride synthesis in adipose tissue (promoting fat storage). Thus, regulators of insulin production, signaling, and sensitivity greatly influence nutrient handling and energy homeostasis. In human pancreatic b cells, glucose induces expression of KLF, which directly transactivates the insulin promoter (-) ( Fig. c) . This potentiation of insulin transcription depends on recruitment of histone acetyltransferase p, a commonly recruited coregulator within the KLF family (, ). On the other hand, KLF may have a suppressive effect; as previously mentioned, KLF expressed in insulin-secreting cell lines reduces insulin production (). KLF alters insulin secretion via crosstalk between adipose tissue and the pancreas. Nagare et al. () demonstrated that overexpression of adipose tissue KLF is protective against diet-induced oxidative stress by suppressing SCD in adipose tissue, which results in increased insulin secretion by pancreatic b cells and improved glucose tolerance.
Beyond regulating insulin production, KLFs also dictate tissue sensitivity to insulin, the most classically described being KLF. In vitro overexpression of KLF in adipocytes and myocytes drives transcription of the insulin-sensitive glucose transporter GLUT and facilitates significant glucose uptake into cells (). This likely occurs via KLF cooperation with MEFA on the Glut promoter (). Conversely, knockdown of KLF in adipocytes reduces insulin-mediated glucose uptake and glycolysis (). Other KLFs known to affect insulin sensitivity include KLF and KLF. Adipose KLF binds to and inhibits transcription of Fama, which encodes the insulin-sensitizing factor adipolin (, ). Global deletion of KLF protects mice from diet-induced obesity and metabolic disease, including insulin resistance (). Interestingly, adipose KLF positively regulates adipolin expression, and high-fat diet-induced inflammation represses KLF expression, providing an additional link between metabolic inflammation and insulin resistance (). Whereas KLF and KLF alter adipose-driven signals affecting insulin sensitivity, KLF modifies hepatic insulin signaling. KLF is downregulated in multiple cell types of diabetic mice and humans, and its forced overexpression in hepatocytes facilitates insulin-mediated glucose uptake through PIK/Akt activation (). In addition, hepatic KLF overexpression protects against hyperglycemic-and hyperinsulinemic-stimulated glucose uptake inhibition seen in patients with diabetes. Therefore, KLF may represent a dominant positive regulator of insulin signaling within the liver. On the other hand, in mouse models of either global or hepatic deletion of KLF, animals demonstrate protection from high-fat diet-induced hepatic steatosis and improved insulin sensitivity and glucose tolerance. This may be due to KLF's posttranscriptional effects on Ppara and its downstream targets (i.e., Trb and Pepck) that regulate insulin signaling and hepatic gluconeogenesis ().
Glucocorticoids affect systemic glucose handling by promoting hyperglycemia through the induction of hepatic gluconeogenesis and inhibition of skeletal muscle and adipose glucose uptake. Excess glucocorticoid release induces insulin resistance and other manifestations of metabolic syndrome, as seen in Cushing syndrome (). KLFs are well-known mediators of nuclear receptor signaling, including acting downstream of glucocorticoid receptor (GR) (). Studies investigating the functional significance of this are largely limited to cell growth and differentiation (-). In skeletal muscle, glucocorticoid signaling upregulates KLF and improves endurance performance, possibly through upregulating amino acid and lipid metabolic programs (). In mouse embryonic fibroblasts, KLF is a direct target of GR. GR stimulation augments KLF expression and contributes to KLF's well-documented role in promoting adipogenesis and differentiation (, ). Although glucocorticoids and KLFs have independently been shown to control glucose handling, additional work is needed to investigate how these players interact to regulate metabolic homeostasis.
Glucose homeostasis
The body imposes tight constraints on glycemia. Because the brain almost exclusively relies on glucose, plasma glucose levels below~ mM in humans predictably manifest as largely neurologic sequelae. Hyperglycemia occurs most often in the context of diabetes mellitus, and chronically elevated levels of glucose contribute to a host of morbidities, not the least of which are neuropathy and vasculopathy. Thus, robust physiologic mechanisms, especially in the liver, ensure the maintenance of euglycemic conditions. During times of nutrient excess, the liver stores energy in the forms of glycogen and fat. During fasting, the liver buffers glucose levels through glycogenolysis before proceeding to gluconeogenesis, then to ketogenesis while also incorporating substrates released from protein breakdown in skeletal muscle in periods of extended nutrient deprivation.
KLF was the first KLF to be linked to metabolism through its regulation of the glucose transporter GLUT in adipose and muscle cells (). Subsequently, KLF, KLF, KLF, and KLF were found to have important roles in regulating hepatic gluconeogenesis ( Fig. a) . KLF, KLF, and KLF in the liver are all induced by fasting and boost expression of gluconeogenic enzymes, whereas KLF expression is downregulated in fasting (-). Accordingly, studies have shown that the silencing or overexpression of these factors affects systemic glucose dynamics in both physiology and pathology.
KLF coordinates with peroxisome proliferatoractivated receptor-g coactivator a (PGC-a) and directly acts on the promoter of phosphoenolpyruvate carboxykinase (Pepck) , an enzyme that catalyzes an irreversible step in gluconeogenesis, to initiate Pepck gene transcription (). Liver-specific KLF depletion results in reduced expression of PEPCK and glucose--phosphatase (GPase). Interestingly, KLF also regulates a number of enzymes involved in amino acid catabolism [e.g., alanine aminotransferase  (Alt), proline dehydrogenase (Prodh), and tryptophan ,-dioxygenase (Tdo)] (, ). Tellingly, mice with systemic KLF deficiency demonstrate impaired skeletal muscle amino acid catabolism (discussed later in this article) and, consequently, these animals are unable to mobilize and use gluconeogenic substrates once glucose and glycogen stores are depleted, thus leading to severe hypoglycemia after an overnight fast (). KLF, therefore, not only controls hepatic gluconeogenic enzymes directly but also influences the supply of gluconeogenic carbon substrates from skeletal muscle and their use in the liver. KLF's role in gluconeogenesis is important in mediating the therapeutic effects of metformin, a medication used for the treatment of type  diabetes. Administration of metformin to either cultured hepatocytes or mice results in reduced KLF expression and reduced glucose production. Upon restoration of KLF expression, these effects on glucose output are attenuated ().
Importantly, KLF's effects on blood glucose levels occur in a circadian fashion, allowing organism behavior (e.g., feeding and sleeping) to be synchronized with nutrient handling throughout the day/night cycle. Klf is subject to CLOCK/BMAL control and its rhythmicity is abolished in mice with mutations of core clock genes (e.g., Per/) (). Circadian glucose homeostasis is critically dependent on rhythmic KLF expression and through it, coordination of diurnal amino acid supply and use in the liver as gluconeogenic substrates (). In hepatocytes as well, KLF expression oscillates on a -hour cycle, suggestive of its role in conferring rhythmicity to hepatic glucose metabolism. A second hepatic KLF, KLF, also possessed a robust circadian pattern that is abolished in clock-deficient Bmal knockout mice, and luciferase promoter assays have demonstrated that the Klf promoter is a target of the CLOCK-BMAL heterodimer (). In the liver, transcriptome data from KLF15) regulate the expression of key hepatic enzymes involved in amino acid (AA) catabolism (e.g., Alt1, Prodh, Tdo2) and gluconeogenesis (e.g., Pepck, G6Pase). These processes provide a steady source of glucose for glucose-obligate organs such as the brain. (b) KLF15 in skeletal muscle regulates branched-chain AA catabolism. These AAs are shuttled to the liver and used as carbon substrates for gluconeogenesis. (c) In the pancreas, glucose induces KLF11 expression, which leads to increased insulin production. KLF7 opposes the action of KLF11. KLF3 and KLF15 increase insulin sensitivity in WAT, allowing for enhanced glucose uptake. Alt1, alanine aminotransferase 1; BCAT2, branchedchain amino acid transaminase 2; G6Pase, glucose-6-phosphatase; Pepck, phosphoenolpyruvate carboxykinase; Prodh, proline dehydrogenase; Tdo2, tryptophan 2, 3-dioxygenase; TCA, tricarboxylic acid; WAT, white adipose tissue. [© 2019 Illustration Presentation ENDOCRINE SOCIETY] Klf 2/2 mice reveal enrichment of  genes involved in lipid and carbohydrate metabolism, the majority of which are clock controlled. Compared with wild-type mice, male Klf 2/2 mice have hyperglycemia, both postprandially and during fasting, and this phenotype is accompanied by a time-of-day dependent upregulation of Pepck. Studies also show that KLF directly suppresses Pepck promoter activity (). Disruption of circadian rhythmicity in humans such as that seen in shift work is well documented to be associated with metabolic pathologies such as type  diabetes mellitus TDM) (, ). Given this, the role of KLF and KLF oscillations in regulating human metabolic disease is a potentially important area of investigation.
Overexpression of either KLF or KLF in primary hepatocytes increases cellular glucose output as a result of these transcription factors directly binding and activating the promoter of Pgc-a (, ). Pgc-a is an important transcription factor that drives the expression of a number of key gluconeogenic enzyme genes, such as Pck, which encodes PEPCK, and Gpc, which encodes GPase (). In vivo evidence demonstrates that forced expression of hepatic KLF and KLF in CBL/J mice leads to increased plasma glucose levels and glucose intolerance. Interestingly, hepatic knockdown of these KLFs in a diabetic mouse model results in normalization of blood glucose levels and improvement in glucose tolerance (, ).
Hepatic KLF acts antiparallel to KLF, KLF, and KLF (). In the fasted state, PGC-a and PEPCK are elevated, whereas KLF expression is low. KLF acts on the Pepck promoter to suppress transcription. Concordantly, hepatic silencing of KLF leads to disruptions in glucose homeostasis; whereas, adenovirus-mediated overexpression of hepatic KLF alleviates hyperglycemia and glucose intolerance in db/ db mice ().
Lipid flux and use Efficient long-term energy storage falls primarily within the purview of white adipose tissue (WAT), a major regulator of lipid partitioning in the body. When caloric intake outstrips the rate of expenditure, excess energy is stored via either increased commitment of stem cells to the adipocyte lineage or hypertrophy of mature white adipocytes. The activation of lipogenic programs and the uptake of lipids from the circulation trap nearly % of postprandial fatty acids liberated by lipoprotein lipase (). Endocrine functions are also ascribed to WAT via the release of secreted proteins, including leptin, adiponectin, resistin, and others, as previously discussed (). These processes are sensitive to adipogenic stimuli such as insulin or glucocorticoids, and they are subject to control by master transcriptional regulators such as PPARg and the C/EBPs ().
Several KLF family members are positive and negative regulators of adipocyte development (Fig. a) , as reviewed elsewhere (). Their effects depend on timing and degree of expression during differentiation, which complicates the interpretation of studies that inactivate the KLFs throughout the process of white adipocyte differentiation. Early studies reported that KLF levels are elevated early during differentiation of T-L cells, and KLF is required for not only DLKmediated transcriptional regulation of adipogenesis but for the full adipogenic program (, ). However, in studies using cells differentiated from primary progenitors, KLF was required for AbAR signaling-mediated inhibition of adipogenesis (). More recently, a report using conditional KLF-KO mice suggested that KLF may be dispensable for adipogenesis in vivo. KLF is required for T-L differentiation and acts by driving C/EBPa and PPARg activity (). Similarly, KLF activates PPARg and promotes porcine adipocyte differentiation, and two separate reports show KLF is important in the early and middle phases of T-L differentiation through its action on the promoters of C/EBPb and PPARg, respectively (-). C/EBPb and D induce KLF during adipogenesis and together activate PPARg and Krox (an early adipogenic factor), a process that may require GSKb activity (, ). Evidence of KLF's role as a positive regulator of adipocyte development comes from studies with Klf +/2 mice, which demonstrate impaired WAT development and smaller WAT mass; additionally, isolated embryonic fibroblasts from these animals exhibit poor differentiation (). Recent transcriptomic analysis of adipogenesis using human stromal cells identified KLF as highly upregulated during differentiation (), consistent with earlier reports that KLF in T-L adipocytes is required for PPARg expression and normal differentiation (). KLF modulation of adipogenesis is sensitive to several upstream signals, including glucocorticoids, interleukin-, and circadian regulation (, , ).
Several KLFs are negative regulators of adipogenesis. KLF was the first family member identified as a negative regulator of adipogenesis by virtue of its ability to inhibit PPARg in T-L cells (). Consistent with this observation, mouse embryonic fibroblasts from Klf 2/2 embryos were shown to differentiate early in the adipogenic process (). Interestingly, in the context of adipogenesis, Klf is subject to posttranscriptional regulation via Staumediated mRNA decay, suggesting an additional level of complexity in the regulation of adipogenesis (). KLF decreases during T-L differentiation, and forced overexpression of KLF in T-L cells inhibits differentiation (). Mechanistically, KLF may recruit CtBP corepressors and together, repress the C/EBPa promoter; therefore, with diminishing KLF levels, C/EBPa is de-repressed in adipocytes.
Although initially paradoxical, the finding that Klf 2/2 mice have smaller fat pads than control cohorts may be rationalized by early and inappropriate activation of C/ EBPa before its normal rise during differentiation (). Similar to overexpression of KLF, overexpression of KLF in T-L adipocytes and chicken preadipocytes also inhibits adipogenesis. On the other hand, KLF inhibits T-L differentiation through the recruitment of HDAC to repress Dlk ().
Classically recognized for their thermogenic capabilities, brown adipose tissue as well as "inducible brown adipocytes" or "beige/brite adipocytes," are emerging as important contributors of systemic metabolism because they are able to convert excess nutrients into heat. In response to cold, brown adipose tissue upregulates expression of uncoupling protein  (UCP), a unique protein that uncouples the electron transport chain to produce heat; WAT can activate specific gene programs to induce "browning" to produce beige/brite adipocytes with thermogenic capabilities. KLFs affect brown adipocyte differentiation and browning of WAT. KLF and KLF are highly expressed in brown adipocytes and directly regulate the expression of UCP during brown adipocyte differentiation (). Furthermore, KLF associates with PPARg superenhancers to activate "browning" genes to induce beige adipocytes in the context of rosiglitazone stimulation (, ). Whereas KLF is essential for promoting brown adipocyte differentiation, KLF overexpression inhibits PPARg in brown preadipocytes and consequently reduces differentiation (). KLF control of the size of the brown and beige adipocytes pool ultimately affects the efficiency with which the body burns excess energy and maintains nutrient homeostasis.
Several KLFs influence lipid metabolism through control of hepatic lipoprotein synthesis and lipogenesis (Fig. b) . As a direct transcriptional regulator of Apoa, KLF controls high-density lipoprotein cholesterol levels in circulation and, therefore, cholesterol efflux to the liver (). Interestingly, this role in lipoprotein assembly may be ancient; control of lipoprotein levels in murine models is mirrored in KLF regulation of lipoproteins in Caenorhabditis elegans. Klf mutations in C. elegans result in decreased expression of dsc- and the five vit genes, which are C. elegans orthologs of mammalian microsomal triglyceride transfer protein and apolipoprotein B, both of which are critical for lipoprotein assembly and secretion (, ). KLF exerts direct control over lipid metabolism in a circadian fashion in the liver; as mentioned, the Klf promoter contains an enhancer-box response element and therefore acquires the CLOCK-BMAL heterodimer, resulting in rhythmic expression of a majority of KLF regulated genes involved in lipid metabolism (as well as gluconeogenesis), such as Srebpc (). The Klf promoter also contains several carbohydrate response elements, one of which is used by carbohydrate response element-binding protein to directly couple glucose levels in the liver with hepatic lipogenesis ().
Independent of adipocyte number, KLF also regulates lipogenesis and lipolysis. KLF, in physical association with the lipogenesis regulator LXR/RXR, regulates transcript levels of Srebf to exert control over the hepatic lipogenic program and influence triglyceride levels in the circulation. Upon fasting, RIP forms a repressive complex with LXR/RXR and KLF, thus reducing Srebp-c expression and subsequent lipogenic enzyme expression. While in the postprandial state, hepatic KLF levels decrease, and the coactivator SRC- replaces RIP to drive SREBP-c promoter activation (). Also in the postprandial state, insulin induces WAT KLF, which, in turn, suppresses lipolysis and enhances lipogenesis (Fig. c) . Adipose tissue-specific KLF knockout mice exhibit decreased adiposity, lower levels of leptin, elevated levels of adiponectin, enhanced insulin sensitivity, improved endurance-exercise capacity, and enhanced liver ketogenesis (). Indeed, both systemic KLF-deficient and adipose tissuespecific KLF-deficient mice are protected from diet-induced obesity (, ).
Amino acid metabolism and nitrogen disposal Amino acids serve as an energy shuttle in the body: Carbon skeletons from amino acids are used by major metabolic pathways such as gluconeogenesis, ketogenesis, and fatty acid synthesis. Owing to mammals' inability to fix nitrogen, they detoxify the body of nitrogen byproducts of amino acid metabolism by converting ammonia to urea. Of the KLFs, KLF, in particular, has been heavily implicated in the control of amino acid metabolism and subsequent nitrogen detoxification and disposal (). In addition, KLF plays a key role in controlling the circadian rhythmicity of these processes, allowing for the coupling between behavior (e.g., sleeping and eating) and nutrient handling by the body.
In the fasted state, skeletal muscle releases alanine and other amino acids into the circulation for uptake and use by the liver for gluconeogenesis. This process of transferring and repurposing nutrients is critical to preserving systemic euglycemia and the continued function of obligate glucose users such as the brain. Systemic KLF-deficient mice demonstrate derangements in serum amino acid concentrations: Specifically, proline, tyrosine, leucine, and valine levels are decreased, and glutamine levels are increased (). Gray et al. () found that Klf 2/2 mice have significantly reduced expression of several amino acid degradation enzymes in the liver and skeletal muscle: Alt, Prodh, Tdo, branched-chain aminotransferase  (Bcat), and -hydroxyphenylpyruvic acid dioxygenase (Hpd) (Fig. b) . Consequently, compared with control animals, these KLF-deficient mice experience severe hypoglycemia in the contexts of overnight fasts and prolonged high-protein diets ().
In humans, nitrogen homeostasis exhibits -hour periodicity. Consequently, plasma urea concentration and several amino acids [e.g., alanine and the branched-chain amino acids (BCAA)] exhibit circadian rhythmicity (). Jeyaraj et al. () have demonstrated that the expression of amino acid metabolism and nitrogen detoxification genes exhibit diurnal rhythmicity orchestrated by KLF in mice. The diurnal rhythmicity of Alt and Bcat expression is disrupted in Klf 2/2 mice; these animals have decreased alanine and glutamine concentrations and a buildup of BCAA concentrations. In addition, systemic KLF deficiency results in reduced ornithine transcarbamylase activity, increased urine ammonia levels, and cognitive dysfunction resulting from hyperammonemia, clearly indicating KLF's important role in nitrogen homeostasis ().
In the myocardium, cardiac KLF has a role in rhythm, imparting diurnal oscillations to transcripts of genes involved in BCAA catabolism. KLF underlies temporal partitioning of cardiac functions, such that during the resting phase, remodeling and repair processes dominate, whereas during the active phase, there is an enrichment of catabolic pathways (, ).
It is thought that dysregulation of KLF-mediated amino acid metabolism plays an important role in the progression of muscle pathologies (e.g., heart failure and Duchenne muscular dystrophy) (, , ). Several studies have shown that these diseases are associated with loss of KLF, consequent downregulation of BCAA catabolism enzymes, and eventual reactive oxygen species' release secondary to toxic buildup of BCAAs (, ). Elucidating these pathways may serve as a basis for developing therapies against striated muscle pathology; indeed, KLF overexpression in skeletal muscle or BCAA supplementation in murine spinal muscular atrophy models (Taiwanese Smn 2/2 , SMN, and Smn B/2 ) extended lifespan and improved markers of muscle atrophy ().
Thus, energetic substrate distribution is highly dynamic and dependent on coordinated KLF activity across multiple tissues. On the one hand, KLFs in liver and WAT regulate bidirectional movement of nutrients during fasting or fed states. On the other hand, KLFs in striated muscle often control gene programs that promote unidirectional uptake of substrates for oxidation. This may be mediated by circulating factors like insulin or glucocorticoids, but is certain to include more (e.g., adipokines).
Energy Consumption/Substrate Oxidation
Hormonal signals and the delivery of fatty acid substrates to organs of high metabolic demand use metabolic programs that uptake these lipids, transport them into mitochondria, and eventually oxidize them as sources of energy. Skeletal and cardiac muscle account for~% of the body's energy expenditure at rest but nearly % during aerobic exercise. Within these tissues, several KLFs are critical regulators of lipid flux and oxidation (, ). Indeed, because cardiac and skeletal muscles are highly metabolically plastic and preferentially consume fat sources of energy, KLF activity couples muscle substrate preference with energy supply.
As first observed by Oishi et al. () , Klf is induced in the soleus muscle of mice fed a high-fat diet, and Klf +/2 mice demonstrated enhanced oxygen consumption but similar respiratory exchange ratios compared with wild-type mice, presumably due to Klf regulation of CPTb, ACADM, ACOX, UCP, and UCP in skeletal muscle. These target genes are shared by the ligand-inducible and lipid metabolism regulator PPARD (), such that transcriptional activity of fatty acid metabolism genes in skeletal muscle is mediated by a multimember protein complex including KLF, PPARD, as well as C/EBP, NCoR, and SMRT, wherein association is at least partly determined by SUMOylation (). Our group has identified KLF as an essential regulator of fat use in skeletal muscle in the context of exercise and fasting. Acute exercise induces KLF in muscle and KLF is more highly expressed in slow-twitch soleus muscle than in fast-twitch vastus lateralis, a phenomenon consistent with muscle fiber-type switching in exercise (). Klf 2/2 mice experience poor exercise tolerance and decreased mitochondrial oxidation coincident with lowered expression of genes involved in fatty acid transport and oxidation, despite compensatory increases in Ppargca and Esrrg (). Importantly, these mice exhibit an increased respiratory exchange ratio as well as elevated plasma fatty acid concentrations after exercise, suggesting that in the absence of KLF, these mice shift substrate preference in skeletal muscle toward carbohydrates and away from lipid oxidation (). Furthermore, KLF is responsive to fasting and controls expression of other fasting-inducible genes (). KLF activity in skeletal muscle, therefore, shapes intracellular lipid use pathways to respond to nutrient availability and composition (Fig. a) .
Much like the skeletal muscle KLFs, several cardiac KLFs broadly control lipid flux and oxidation in response to physiologic state, thereby enabling the enormous metabolic flexibility exhibited by the heart (Fig. b) . Cardiomyocyte Klf is fasting inducible and requisite for cardiac adaptation to fasting (). It is also elevated during postnatal maturation as the murine fetal heart transitions toward adulthood and dramatically increases its reliance on oxidative metabolism (). Just as in skeletal muscle, higher plasma levels of fatty acids and triglycerides in the Klf 2/2 mouse exist in stark contrast to the reduced levels of intramyocardial fatty acids and triglycerides, and mitochondria isolated from Klf 2/2 mice oxidize longchain fatty acids poorly (). In this context, KLF associates with PPARa as well as coactivators such as p to cooperatively control lipid gene expression and transduce incoming physiologic signals to cellular metabolism (). Recent work by Drosatos et al. () points to KLF as another regulator of fatty acid oxidation through its control of PPARa expression, suggesting that KLF control of cardiomyocyte fat metabolism occurs not only in cooperation with nuclear receptors but also at a level upstream.
In the heart, KLF control of oxidative metabolism extends to broad regulation of mitochondrial biogenesis, dynamics, and degradation. Deletion of cardiac KLF in mice reveals altered expression of mitochondrial genes, disordered mitochondrial morphology (e.g., fragmentation, reduced volume density, reduced mitochondrial genomic DNA), and impaired mitochondrial respiration (). Specifically, both small and giant mitochondria accumulate in KLF knockout mouse hearts, suggestive of a defect in mitochondrial fission and fusion processes as well as autophagic clearance (). These changes ultimately reduce cardiac resiliency in the face of high metabolic requirement, for example, during postnatal cardiac maturation, with normal aging, and in response to "Genome-wide studies have identified important human KLF genetic variation associated with a multitude of metabolic pathologies." pressure overload (, ). KLF associates with PGC-a and ERRa to form a tripartite molecular complex and cooperatively regulate transcription of common gene targets, notably those involved in mitochondrial biogenesis and autophagy; indeed, KLF is required for ERR/PGC-a gene activation (). Independent of ERR/PGC-a, KLF also regulates several mitochondrial encoded genes ().
Dysregulation of KLFs in Human Disease
Obesity and metabolic disease remain pervasive health concerns, increasing risk of multiple leading causes of mortality, including cardiovascular disease and cancer. Despite this, therapeutic options targeting these processes remain only partially effective at preventing or slowing progression of disease. Given the widespread reach of KLFs in physiological metabolic control, it is not surprising that genome-wide studies have identified important human KLF genetic variation associated with a multitude of metabolic pathologies. Variants in KLF, KLF, KLF, and KLF are associated with diabetes, and KLF, KLF, KLF, KLF, and KLF are associated with increased body mass index (BMI). In addition, single nucleotide polymorphism (SNP) variants in KLF and KLF are associated with NAFLD, whereas KLF variation is also correlated with dyslipidemia and coronary artery disease (CAD). We focus here primarily on evidence of KLF involvement from human studies.
KLFs in diseases of glucose homeostasis
Numerous studies have implicated KLFs in human metabolic diseases of glucose intolerance and insulin resistance such as TDM and maturity onset of diabetes in the young (MODY). Several different groups have recently identified SNPs in KLF that are associated with TDM susceptibility (-). Although most disease-associated SNPs are cis-acting gain-or loss-of-function mutations, Small et al. () showed that SNPs within the KLF loci are also associated with trans-mediated changes of expression in other genes important in dictating metabolic parameters, such as insulin resistance. Remarkably, one gene that was identified as being under trans regulation of KLF in metabolic disease is KLF, an example of intrafamily regulation not uncommon to the KLFs. Interestingly, in a recent follow-up study, the authors observed that the cis and trans effects of this KLF mutation disproportionately skew toward female mice (). After ruling out sex hormone-based dimorphism, the authors attributed this phenomenon to females requiring higher basal levels of KLF, as evidenced by elevated expression in adipose tissue of females compared with males. In addition to mutational events affecting KLF function, Bacos et al.
() showed that epigenetic alterations in KLF might also contribute to metabolic disease. In pancreatic islets and blood, KLF methylation increases with age and is associated with altered insulin secretion commonly seen in the aging pancreas (). These studies demonstrate that loss of KLF function through mutational or epigenetic means is highly associated with metabolic disease.
Variants of KLF are also associated with diabetes pathogenesis in humans. SNPs in KLF were first identified in the context of families with early-onset diabetes, hence its characterization as the causative mutation in MODY (, ). Also, one variant has been identified within the insulin promoter that prohibits KLF binding, leading to neonatal diabetes mellitus (). Mechanistic investigation has elucidated widespread effects of KLF in glucose homeostasis. In pancreatic b cells, KLF is induced by glucose and augments insulin production (). The GlnArg variant of KLF is a gain-of-function mutation that permits KLF binding of the corepressor mSinA, eventually repressing insulin transcription (). Conversely, the AlaSer variant of KLF inhibits the ability of the transcriptional regulatory domain  (TRD) to bind to guanine nucleotide-binding protein b (Gb), thus diminishing glucose-stimulated insulin secretion (). In addition to regulating insulin production, KLF interacts with p and promotes transcription of pancreatic-duodenal homeobox- (Pdx-), a master regulator of pancreas development and function (, ). Interestingly, mutations in Pdx- are causative for MODY (), suggesting there is a regulatory network of MODY genes in which KLF participates.
Although less well characterized, other KLFs have also been identified in genome-wide association and expression studies to play a role in diabetes including KLF and KLF (-). For example, the KLF rs SNP is associated with diabetic cardiomyopathy and was a predictor of hospitalization for heart failure (). Considering the pervasive role of KLF in multiple facets of metabolism, it remains one of the most promising regulators to target in human metabolic disease and, as such, requires prompt and thorough exploration.
KLFs in obesity
Although there is considerable overlap between the pathogenesis of diabetes and obesity, several KLF variants are only associated with increased body mass and adiposity. For example, a link between BMI and KLF SNP exists in East Asian populations; however, it is not associated with increased risk of diabetes (). Interestingly, the rs SNP of KLF demonstrates gene-gene interactions with an SNP at the myostatin (MSTN) locus, offering possible mechanistic insight that needs further exploration (). Additional SNPs in KLF and KLF have been identified that are associated with obesity (, ). In addition to KLF SNP variants contributing to metabolic disease, alterations in KLF gene dosage within cells, such as that seen in copy number variations (CNVs), epigenetic silencing, and transcriptional regulation, have a demonstrated link to human obesity. In children with elevated BMI, KLF is hypermethylated in blood and metabolic cells (e.g., preadipocytes, pancreatic islets) (). Interestingly, in their study, Koh et al. () also identified KLF SNPs in these patients, associated with hypermethylation of CpG sites, suggesting that polymorphisms in KLF may also dictate epigenetic changes that drive disease. In a recently published article exploring CNVs as a potential mechanism of disease in isolated cases of early-onset obesity, KLF CNV was observed to be associated with higher BMI (). Unsurprisingly, adipose mRNA expression of KLF was also lower in these obese patients. Given the evidence that pathologic expression of multiple KLFs is capable of contributing to obesity, correction of KLF expression by genetic, epigenetic, or transcriptional means represents an exciting potential strategy in combating obesity.
KLFs in dyslipidemia
Abnormal concentrations of plasma lipids and carrier proteins are important risk factors for cardiovascular disease as well as for nonalcoholic fatty liver disease (NAFLD), both of which are associated with development of metabolic syndrome. Because KLFs are important effectors of lipid handling, it is unsurprising that KLF variants are seen in human dyslipidemia. One particular SNP at the KLF locus is associated with decreased high-density lipoprotein cholesterol and an elevated risk for CAD (, ). Similar to trends seen with glucose dynamics (), there are also sex-specific differences in lipid profiles between males and females with the rs KLF SNP, further demonstrating the predilection of this variant to more robustly affect female patients (, ).
NAFLD is a consequence of increased hepatic triglyceride accumulation, eventually leading to inflammatory damage and fibrosis. Although KLF variants contributing to dyslipidemia may also increase risk for NAFLD development, there is a paucity of literature to confirm this. Instead, studies suggest that SNPs in KLFs may dictate the severity of progression in patients with NAFLD. Indeed, two reports identify a loss-of-function KLF SNP, which is linked to advanced NAFLD (, , ), and another two have identified a loss-of-function SNP in KLF that decreases risk of fibrotic progression in patients with NAFLD (, ). Interestingly, one splice variant of KLF shown to be protective against NAFLD progression, KLF-IVS-A, also protects against other metabolic predictors of NAFLD severity, such as insulin resistance by restricting KLF's activation of glucokinase transcription (). In addition to KLF, KLF has also been linked to mouse models of NAFLD. KLF expression promotes NAFLD by positively regulating hepatocyte expression of CD, a cell surface receptor responsible for fatty acid uptake into the liver (). Currently, however, no human correlates have been found implicating KLF variants with amelioration of NAFLD.
Dyslipidemia is also highly correlated with the progression of atherosclerosis . The KLFs are heavily implicated in the pathogenesis of atherosclerosis, predominantly through their involvement in the vascular inflammatory response to oxidized low-density lipoprotein (). As previously discussed, SNPs in KLF are associated with CAD, a manifestation of atherosclerosis (). Despite the large body of evidence in mice and cell culture implicating KLFs in the formation of atherosclerosis, there is a relative dearth of evidence describing patients with vascular disease who have KLF mutations. Additional investigation is necessary to fully understand the importance of KLFs in human atherosclerotic disease.
Conclusion
Evidence over the past two decades has positioned the KLFs as essential regulators of metabolism by virtue of their own actions and coordination with canonical nuclear receptor signaling. Alone or in concert with coregulators, KLFs affect a broad spectrum of metabolic functions in nearly every major organ and in response to diverse physiologic needs. KLF transcriptional output directs nutrient intake, systemic trafficking (i.e., glucose flux, lipid partitioning, amino acid catabolism), and oxidation for energy. The physiologic importance of the KLFs is reflected in genome-wide association studies and other large-scale studies that routinely identify KLF genetic variants associated with metabolic disease. Many aspects of KLF regulation of metabolism remain to be elucidated. The profound impact of this complex family of metabolic regulators on human health and disease is only now becoming clear, and it is expected that future investigations will assign new metabolic roles to the KLFs.
